4 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
| Phase 1 | 1 | Terminated 1 |
Follow Chronic Renal Failure: new trials by email Literature Review of Chronic Renal Failure trials Research Report on Chronic Renal Failure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD (EU) peginesatide - Chronic Renal Failure, Chronic Kidney Disease | Phase 2 | Terminated | Affymax | 114 | 2006-11-01 | 2012-06-29 |
| Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD peginesatide - Chronic Renal Failure, Chronic Kidney Disease | Phase 2 | Terminated | Affymax | 81 | 2006-09-01 | 2012-06-29 |
| Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease Placebo, peginesatide - Anemia, Chronic Kidney Disease | Phase 2 | Terminated | Affymax | 17 | 2005-03-01 | 2012-12-21 |
| Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis edifoligide (E2F Decoy) - Hyperplasia, Chronic Renal Failure | Phase 1 / Phase 2 | Terminated | Anesiva, Inc. | 2004-05-01 | 2005-07-19 |
Kidney Failure, Chronic (4) · Anemia (3) · Renal Insufficiency, Chronic (3) · Hyperplasia (1)
Chronic Disease (4) · Disease Attributes (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Kidney Diseases (4) · Male Urogenital Diseases (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Renal Insufficiency (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Renal Insufficiency, Chronic (1)
hematide (3) · peginesatide (3) · edifoligide (1)
Affymax (3) · Anesiva, Inc. (1)
United Kingdom (2) · United States (2) · Bulgaria (1) · Poland (1) · Romania (1)
Vice President, Clinical Development (2)
2005 (1)